Quantum BioPharma Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its lead drug candidate, Lucid-MS, toward Phase 2 clinical trials following successful Phase 1 safety and tolerability studies, according to a recent BioMedWire editorial. Unlike conventional multiple sclerosis (MS) treatments that primarily target the immune system, Lucid-MS is a patented, first-in-class non-immunomodulatory neuroprotective therapy designed to directly protect the myelin sheath damaged by the disease.

The editorial highlights that Lucid-MS has demonstrated the ability to prevent and reverse myelin degradation in preclinical models, supported by more than a decade of scientific research. This approach could represent a significant shift in MS treatment, as current therapies often focus on reducing immune attacks on myelin but do not directly repair or protect the myelin sheath. If successful in Phase 2 trials, Lucid-MS could offer a new option for patients who do not respond adequately to existing immunomodulatory drugs.

Quantum BioPharma is also collaborating with researchers at Massachusetts General Hospital to validate a novel PET imaging technique that may enable direct measurement of myelin integrity in MS patients. This imaging tool could provide a more accurate way to assess disease progression and treatment efficacy, potentially accelerating the clinical development of not only Lucid-MS but also other myelin-protective therapies.

The feature additionally noted developments across the neurological and immune-mediated disease sectors, including programs from major pharmaceutical companies such as Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB), and Clene Inc. (NASDAQ: CLNN). This context underscores the broader industry interest in advancing treatments for neurodegenerative conditions.

Quantum BioPharma is a biopharmaceutical company focused on building a portfolio of innovative assets for challenging neurodegenerative, metabolic, and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is dedicated to the research and development of Lucid-MS. The company also invented UNBUZZD, an OTC product aimed at alcohol misuse, which was spun out to Unbuzzd Wellness Inc. Quantum retains a 19.84% ownership stake in Unbuzzd (as of March 31, 2026) and is entitled to royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products for pharmaceutical and medical uses.

The advancement of Lucid-MS into Phase 2 trials marks a critical milestone for Quantum BioPharma and could have important implications for MS patients. If the therapy proves effective, it may offer a novel mechanism of action that directly targets the underlying pathology of MS, potentially improving outcomes for the approximately 2.8 million people worldwide living with the disease.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Quantum BioPharma Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials.

The post Quantum BioPharma Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials appeared first on citybuzz.